Management of Immune-Related Adverse Events (irAEs) in Patients Treated With Immune Checkpoint Inhibitor Therapy

Authored by Open Medicine, published on 2026-05-08 23:16:31.0

  1. Suspected immune-related adverse event (irAE)
    while receiving immune checkpoint inhibitor therapy
    • Immediate triage + diagnostic workup
      Grade severity using CTCAE Assess organ system involved Rule out infection, progression, medication toxicity, and other causes Involve organ specialist early for severe / complex cases
      • Grade toxicity severity
        • GRADE 1 Mild
          • Grade 1 management
            Usually continue ICPI with close monitoring. Exceptions: consider hold / specialist input for neurologic, hematologic, cardiac, or other high-risk presentations.
            • Reassess clinical response after treatment initiation
              Grade 3: typically within 48–72 hours Continue close monitoring until stable / improving
              • Improving to grade ≤1?
                • If improving
                  Continue steroids until controlled Taper over ≥4–6 weeks Provide prophylaxis / monitoring as clinically indicated Resume ICPI only when guideline criteria are met
                  • Resume / continue ICPI
                    only if safe by grade + organ-specific criteria
              • Not improving, worsening, or steroid-refractory?
                • Escalate management
                  Urgent organ-specialist input Add organ-specific immunosuppression when indicated e.g., infliximab or vedolizumab for selected colitis; mycophenolate for hepatitis Avoid infliximab in immune-mediated hepatitis
                  • Discontinue ICPI
                    if grade 4, recurrent severe toxicity, or unsafe to rechallenge
        • GRADE 2 Moderate
          • Grade 2 management
            Hold ICPI for most grade 2 toxicities Consider prednisone 0.5–1 mg/kg/day or equivalent Resume when symptoms / labs improve to grade ≤1 and steroid need is low
            • Reassess clinical response after treatment initiation
              Grade 3: typically within 48–72 hours Continue close monitoring until stable / improving
              • Improving to grade ≤1?
                • If improving
                  Continue steroids until controlled Taper over ≥4–6 weeks Provide prophylaxis / monitoring as clinically indicated Resume ICPI only when guideline criteria are met
                  • Resume / continue ICPI
                    only if safe by grade + organ-specific criteria
              • Not improving, worsening, or steroid-refractory?
                • Escalate management
                  Urgent organ-specialist input Add organ-specific immunosuppression when indicated e.g., infliximab or vedolizumab for selected colitis; mycophenolate for hepatitis Avoid infliximab in immune-mediated hepatitis
                  • Discontinue ICPI
                    if grade 4, recurrent severe toxicity, or unsafe to rechallenge
        • GRADE 3 Severe
          • Grade 3 management
            Hold ICPI Start high-dose corticosteroid: prednisone or methylprednisolone 1–2 mg/kg/day Consider hospitalization depending on organ, symptoms, and trajectory
            • Reassess clinical response after treatment initiation
              Grade 3: typically within 48–72 hours Continue close monitoring until stable / improving
              • Improving to grade ≤1?
                • If improving
                  Continue steroids until controlled Taper over ≥4–6 weeks Provide prophylaxis / monitoring as clinically indicated Resume ICPI only when guideline criteria are met
                  • Resume / continue ICPI
                    only if safe by grade + organ-specific criteria
              • Not improving, worsening, or steroid-refractory?
                • Escalate management
                  Urgent organ-specialist input Add organ-specific immunosuppression when indicated e.g., infliximab or vedolizumab for selected colitis; mycophenolate for hepatitis Avoid infliximab in immune-mediated hepatitis
                  • Discontinue ICPI
                    if grade 4, recurrent severe toxicity, or unsafe to rechallenge
        • GRADE 4 Life-threatening
          • Grade 4 management
            Permanently discontinue ICPI in general. Exception: endocrinopathies controlled with hormone replacement may not require permanent discontinuation.
            • Reassess clinical response after treatment initiation
              Grade 3: typically within 48–72 hours Continue close monitoring until stable / improving
              • Improving to grade ≤1?
                • If improving
                  Continue steroids until controlled Taper over ≥4–6 weeks Provide prophylaxis / monitoring as clinically indicated Resume ICPI only when guideline criteria are met
                  • Resume / continue ICPI
                    only if safe by grade + organ-specific criteria
              • Not improving, worsening, or steroid-refractory?
                • Escalate management
                  Urgent organ-specialist input Add organ-specific immunosuppression when indicated e.g., infliximab or vedolizumab for selected colitis; mycophenolate for hepatitis Avoid infliximab in immune-mediated hepatitis
                  • Discontinue ICPI
                    if grade 4, recurrent severe toxicity, or unsafe to rechallenge
tosprivacyManagement of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update